Evaluating DORAs for Chronic Insomnia: Clinical, Economic, and Patient Perspectives on Treatment Value
In this research, we look at the economic and health impacts of chronic insomnia—its individual and societal costs, as well as patient needs. In light of this burden, we examine how chronic insomnia is currently managed in Canada and how different pharmacological treatment options compare across a broad set of outcomes.
How do the different treatment options compare across a broad set of outcomes? What are the differences between a newer class of pharmacotherapies—specifically the DORA class of insomnia treatments—and the commonly prescribed legacy treatments (benzodiazepines and Z-drugs)? What are the systemic barriers to equitable access, and how can we improve treatment outcomes across Canada’s diverse population?
Read the impact paper briefing to get our full analysis.
Cette publication est disponible en français.
Key findings
Beyond sleep: The hidden burden of insomnia in Canada
The cost-consequences of chronic insomnia in Canada
Aligning evidence, practice, and policy
Appendix A: Methodology
Appendix B: Bibliography
